DOI: 10.1001/jama.2025.9894 ISSN: 0098-7484

HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccine

Kristen M. Marks, Minhee Kang, Triin Umbleja, Andrea Cox, Karen J. Vigil, Anchalee Avihingsanon, Patcharaphan Sugandhavesa, Leolin Katsidzira, Josphat Kosgei, Hugo Perazzo, Jennifer Price, Stephanie Caruso, Kevin Knowles, Beverly L. Alston-Smith, Parita Rathod, Kenneth E. Sherman, , Oladapo Alli, Ceora Beijer, Stephanie Caruso, Shawn Chiambah, Lillian Collins, Kim Epperson, Francoise Giguel, Jan Kosmyna, Michael Leonard, Terence Mohammed, Leonard Sowah, Christina Vernon, Sara Zabih, Katrina Shea, Matthew Planchon, Paul Sax, Cheryl Keenan, Joyce Jones, Alex Hessel, Aleen Khodabakhshian, Lisa Mark, Eric S. Daar, Ruben Lopez, Rosemarie Ramirez, Dawn Rosenblum, Dennis Dentoni-Lasofsky, Cecilia Rivas Alfaro, Madhu Choudhary, Jen Sullivano, Rachel Bender Ignacio, Eli Burnham, Teresa Spitz, Raghd Alyatim, Susan Koletar, Robyn Cicarella, Carl J. Fichtenbaum, Michelle Saemann, Leila Hojat, Brenda Brown, Vivek Paul, Claudia Hawkins, Jaclyn Leone, Jonathan Oakes, Cornelius Van Dam, Kelly Phillips, Tracey Watkins, Ericka R. Patrick, Clifford Gunthel, Joslyn Axinn, Nicola Haakonsen, William Short, Pablo Tebas, Keisha Ballentine-Cargill, Nadi Islam, Daniel Finn, Catherine Jerry, Sharlaa Badal-Faesen, Iveshni Govender, Penelope Madlala, Rosie Mngqibisa, Nathalia Soliva, Tania Brum, Breno Riegel Santos, Rita de Cassia Alves Lira, Lerato Mohapi, Nadia Marengo, Sandra Rwambuya, Francis Ntengereze Ssali, Josphat Kosgei, Geoffrey Koskei, Ditlamelo Mareme, Boitshepho Seme, Mulinda Nyirenda, Maxwell Yohane, Michael Yin, Anyelina Cantos, Karen J. Vigil, Mariano J. Lodigiani, Patcharaphan Sugandhavesa, Daralak Tavornprasit, Shobha Swaminathan, Christie Lyn Costanza, Sonal S. Munsiff, Susan E. Hulse, Sonya L. Heath, E. Turner Overton, Megan Dieterich, Carrington Koebele, Anchalee Avihingsanon, Hay Mar Su Lwin, Maria Tarcela Gler, Melchor Frias, Ngan Ta Thi Dieu, Dat Quoc Vu

This study provides the end-of-study results on the durability of seroprotection response in a trial comparing 2- and 3-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG) vs 3-dose hepatitis B vaccine with an aluminum hydroxide adjuvant.

More from our Archive